Effectiveness of Pentagamavunon-0 (PGV-0) in the early phase infection of Dengue-2 virus

Dengue virus infects 50 to 100 million people every year, however, specific treatment or effective antiviral drugs to treat viral infections has not been found yet. Curcumin known has perform the inhibition of ubiquitin-proteasome system that causes a decrease of Japanese encephalitis, one kind of flavivirus. Structural modifications was known to increase the biological activity of curcumin. Pentagamavunon-0 (PGV-0) is known have activity similar to or even better than curcumin. This study aims to determine the effect of PGV-0 in the early phase of infection of dengue- virus 2 (one day of infection). This study includes quasi-experimental study. The method used for the detection of Dengue-2 viruswas immunocytochemistry, whichpreviously tested by PGV-0 cytotoxic test against vero cells. Cytotoxic test results indicate safe concentrations (no toxic effects) of PGV-0 against vero cells is 4.44 µM. Calculation of positive rate compared with the positive control(14.55 ± 7.25) showed that the value of positive rate due to one-day Dengue virus-2 infection with PGV-0 treatment was smaller(3.8 ± 3.89). It was concluded that the PGV-0 is able to decrease the positive rate due to Den-2 infection in the initial period of infection